Central Serous Chorioretinopathy

A visual impairment characterized by the accumulation of fluid under the retina through a defect in the retinal pigment epithelium.

Also Known As:

Central Serous Retinopathy; Central Serous Chorioretinopathies; Central Serous Retinopathies; Chorioretinopathies, Central Serous; Chorioretinopathy, Central Serous; Retinopathies, Central Serous; Retinopathy, Central Serous; Serous Chorioretinopathies, Central; Serous Chorioretinopathy, Central; Serous Retinopathies, Central; Serous Retinopathy, Central

Networked: 1609 relevant articles (158 outcomes, 213 trials/studies)

Relationship Network

Disease Context: Research Results

Eye Diseases: 3522
- Retinal Diseases: 3014
  - Central Serous Chorioretinopathy: 1609

Related Diseases

1.	Choroidal Neovascularization
2.	Atrophy
3.	Macular Degeneration (Age-Related Maculopathy)
4.	Retinal Detachment (Retinal Detachments)
5.	Diabetic Retinopathy (Retinopathy, Diabetic)

Experts

1.	Boon, Camiel J F: 42 articles (12/2022 - 09/2014)
2.	van Dijk, Elon H C: 35 articles (12/2022 - 09/2015)
3.	Chhablani, Jay: 28 articles (10/2022 - 01/2014)
4.	Hoyng, Carel B: 22 articles (10/2022 - 09/2014)
5.	Querques, Giuseppe: 21 articles (11/2022 - 04/2014)
6.	Behar-Cohen, Francine: 19 articles (10/2022 - 11/2013)
7.	Yannuzzi, Lawrence A: 18 articles (10/2021 - 01/2002)
8.	Breukink, Myrte B: 17 articles (01/2022 - 09/2014)
9.	Spaide, Richard F: 17 articles (01/2022 - 01/2002)
10.	Freund, K Bailey: 16 articles (11/2022 - 10/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Central Serous Chorioretinopathy:

1.	1-phenyl-3,3-dimethyltriazene (PDT)IBA 06/01/2019 - "Subfoveal RPED in central serous chorioretinopathy responded well to reduced-fluence PDT, especially in younger patients with less RPED. " 08/01/2021 - "This is a retrospective consecutive interventional study including 559 eyes from 520 patients treated by reduced-fluence PDT for central serous chorioretinopathy. " 09/23/2020 - "To date, half-dose PDT has provided the most encouraging results in this regard, supported by large, multicenter, randomized clinical trials such as the "Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy" (PLACE) trial; however, the role of novel possible non-invasive treatment options is attracting interest. " 04/01/2020 - "The study included 36 eyes of 36 patients with chronic central serous chorioretinopathy who underwent reduced PDT and were followed up for at least 1 year. " 05/01/2023 - "We hypothesize that chronic central serous chorioretinopathy-related chorioretinal dysfunction contributed to the severe PDT-induced local inflammatory reaction that caused the patient's bacillary layer detachment. "
2.	Verteporfin (Visudyne)FDA Link 09/01/2009 - "On the basis of the results of this study and available information regarding the expected rate of spontaneous resolution, 30% verteporfin dose seems to be safe and effective in the treatment of acute central serous chorioretinopathy." 06/01/2023 - "Anatomical and functional impact of verteporfin shortage in patients with chronic central serous chorioretinopathy." 05/19/2023 - "Impact of the ongoing worldwide shortage of verteporfin (Visudyne®) on the visual function of patients with chronic central serous chorioretinopathy." 01/01/2013 - "Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy." 12/01/2012 - "Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy."
3.	Bevacizumab (Avastin)FDA Link 02/01/2010 - "Our results indicate that intravitreal bevacizumab injection may be a new, promising treatment option for select patients with idiopathic persistent central serous chorioretinopathy. " 01/01/2019 - "To evaluate intravitreal bevacizumab (IVB) injection efficacy for the treatment of chronic, atypical, or recurrent central serous chorioretinopathy (CSC). " 01/01/2019 - "TWELVE-MONTH EFFICACY OF INTRAVITREAL BEVACIZUMAB INJECTION FOR CHRONIC, ATYPICAL, OR RECURRENT CENTRAL SEROUS CHORIORETINOPATHY." 02/01/2013 - "To investigate the efficacy of intravitreal bevacizumab injection in patients with acute central serous chorioretinopathy (CSCR). " 02/01/2013 - "The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy."
4.	Retinaldehyde (Retinal)IBA 11/01/2021 - "The continuous application of the covering treatment for 48 h on the sick eye showed positive outcomes with respect to the best-corrected visual acuity, macular retinal thickness, and macular retina functions in the treatment of central serous chorioretinopathy." 10/14/2021 - "Refined understanding of the association of retinal microstructure with current and future (post-treatment) function in chronic central serous chorioretinopathy (cCSC) may help to identify patients that would benefit most from treatment. " 01/01/2017 - "We improved our understanding of central serous chorioretinopathy (CSC), we performed an analysis of noninvasive, high-resolution retinal imaging in patients with active and resolved CSC. " 09/01/2009 - "For each patient, the central serous retinopathy-affected eye had a significantly greater retinal FPF when compared with the retinal FPF of the unaffected eye. " 07/10/2012 - "Letter by Lee et al regarding article, "Spontaneous resolution of central serous chorioretinopathy in a patient with congenital retinal macrovessel"."
5.	Eplerenone (Inspra)FDA LinkGeneric 10/01/2021 - "Background The study examined the efficacy of eplerenone in the management of chronic central serous chorioretinopathy (CSCR) with the aim of short-term observations. " 01/01/2021 - "The VICI trial reported by Lotery et al. is a recent placebo-controlled, randomized trial that examined the efficacy of eplerenone treatment for chronic central serous chorioretinopathy (CSCR) in 104 patients. " 01/01/2020 - "Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy." 11/01/2019 - "To determine the efficacy of oral eplerenone in anatomical and functional improvement in patients with chronic central serous chorioretinopathy (CSCR). " 11/01/2019 - "Effect of oral eplerenone in anatomical and functional improvement in patients with chronic central serous chorioretinopathy."
6.	Indocyanine Green (Cardio-Green)FDA LinkGeneric 05/01/1996 - "Advanced methods for indocyanine green (ICG) video-fluorescence angiography provide improved evaluation of choroidal blood flow disturbances in patients with central serous chorioretinopathy (CSC). " 10/13/2023 - "Choroidal Vascular Changes on Ultrawidefield Indocyanine Green Angiography in Central Serous Chorioretinopathy: CERTAIN Study Report 1." 06/01/2022 - "This study aims to evaluate choroidal vascular alterations in patients with central serous chorioretinopathy (CSC) using ultra-widefield (UWF) indocyanine green angiography (ICGA). " 05/01/2010 - "The purpose of this study was to examine indocyanine green angiography of eyes with central serous chorioretinopathy (CSC). " 01/01/1997 - "[Study of choroidal vascular lesions in central serous chorioretinopathy using indocyanine green angiography]."
7.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/01/2014 - "To evaluate the efficacy of anti-vascular endothelial growth factor (VEGF) compared with observation for treating acute central serous chorioretinopathy (CSC). " 01/01/2023 - "The purpose of this study was to evaluate the role of anti-vascular endothelial growth factor (anti-VEGF) treatment on the functional and structural parameters of chronic central serous retinopathy (CSR). " 10/01/2022 - "The aim of this study was to assess the short-term effect of anti-vascular endothelial growth factor (VEGF) treatment on type 1 macular neovascularization (MNV) secondary to central serous chorioretinopathy (CSCR) and to identify potential predictive factors for treatment response using multimodal imaging. " 01/01/2023 - "Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literature." 01/01/2022 - "Nonhomogenous Hyperreflectivity in the Choriocapillaris Layer on Optical Coherence Tomography Angiography Implies Early Treatment with Anti-VEGF for Central Serous Chorioretinopathy."
8.	Mineralocorticoid Receptor AntagonistsIBA 03/01/2016 - "This pilot study demonstrates that mineralocorticoid receptor antagonists may be effective in treating central serous chorioretinopathy but warrants consideration for future research within a randomized clinical trial." 11/01/2020 - "To evaluate the efficacy of mineralocorticoid receptor antagonist (MRA) for patients with central serous chorioretinopathy (CSCR). " 11/01/2020 - "Efficacy of mineralocorticoid receptor antagonist for central serous chorioretinopathy: a meta-analysis." 02/01/2019 - "Over 3 years have passed since the last publication on the therapeutic principle "Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy" by Maier et al., and numerous new studies have been published on the topic. " 01/01/2019 - "Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials."
9.	Fluorescein (Funduscein)FDA LinkGeneric 01/01/2015 - "We report a case of central serous chorioretinopathy evaluated and treated successfully with SD-OCT without the use of fluorescein angiography." 09/01/2023 - "This study is to assess the possible correlation between findings on fundus autofluorescence (FAF) and fluorescein angiography (FA) in patients with chronic central serous chorioretinopathy (cCSC). " 03/01/2023 - "Case control observational study METHODS: Study included 42 patients (group P) of central serous chorioretinopathy (CSCR) diagnosed with optic coherence tomography (OCT), fundus fluorescein angiography (FFA) which were further sub-grouped into acute(P1), chronic (P2) and recurrent (P3). " 09/01/2021 - "The study looks at the potential applicability of a correlation between leaking areas on fundus fluorescein angiography and a hyperreflective area on the infrared image in optical coherence tomography (OCT) in patients with central serous chorioretinopathy (CSCR)." 06/01/2012 - "This study aims to compare the topographic distribution of retinal pigment epithelium detachment (PED) in central serous chorioretinopathy (CSC) on spectral domain optical coherence tomography (SD-OCT) single-layer retinal pigment epithelium (SL-RPE) map and fluorescein angiography for the first time. "
10.	Spironolactone (Aldactone)FDA LinkGeneric 04/01/2022 - "Therapeutic Efficacy of Spironolactone for Central Serous Chorioretinopathy." 01/01/2018 - "To evaluate the efficacy of oral spironolactone in patients with acute central serous chorioretinopathy (CSC). " 01/01/2021 - "OBJECTıVE: The goal of this study was to investigate the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy (CSC). " 07/01/2023 - "A bullous variant of central serous chorioretinopathy treated with oral spironolactone." 01/01/2021 - "Investigating the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy."

Therapies and Procedures

1.	Photochemotherapy (Photodynamic Therapy) 12/01/2022 - "Although half-dose photodynamic therapy is generally effective for the treatment of chronic central serous chorioretinopathy, coexisting MNV may compromise the outcome; thus, optical coherence tomography angiography-based assessment of chronic central serous chorioretinopathy is important." 01/01/2020 - "Reduced-fluence photodynamic therapy (RFPDT) has proven effective for some patients with chronic central serous chorioretinopathy (cCSC). " 01/01/2023 - "In patients with chronic central serous chorioretinopathy who received a single, foveal, half-dose photodynamic therapy, a significant improvement in structure and function was seen at the final follow-up. " 01/11/2021 - "Central serous chorioretinopathy (CSC) is a disease of unknown etiology, but half-dose photodynamic therapy (hPDT) is well known to be effective for CSC. " 10/01/2016 - "In one of these patients, bilateral chronic central serous chorioretinopathy (CSC) with polypoidal choroidal neovasculopathy was diagnosed, which was effectively treated with full-dose photodynamic therapy. "
2.	Lasers (Laser) 02/01/2013 - "Treatment of patients with acute central serous chorioretinopathy with subthreshold laser improved the best-corrected visual acuity and contrast sensitivity compared with those in the observation group. " 01/01/2020 - "The aim of this study was to analyze the efficacy of micropulse laser treatment (MLT) compared with the continuous-wave laser (CL) in treating eyes with chronic central serous chorioretinopathy (CSC) in a 12-month follow-up study. " 09/01/2022 - "To evaluate the efficacy of subthreshold micropulse laser (SML) treatment for chronic central serous chorioretinopathy (CSC). " 09/01/2022 - "Efficacy of subthreshold micropulse laser for chronic central serous chorioretinopathy: A meta-analysis." 03/05/2022 - "To assess the efficacy of 577 nm subthreshold micropulse laser (SML) treatment for acute central serous chorioretinopathy (CSC). "
3.	Therapeutics 09/03/2012 - "A novel treatment of central serous chorioretinopathy with topical anti-inflammatory therapy." 01/10/2022 - "This retrospective study aimed to assess the safety and efficacy of selective retina therapy (SRT) with real-time feedback-controlled dosimetry (RFD) for chronic central serous chorioretinopathy (CSC) and to evaluate factors predictive of treatment response. " 09/22/2021 - "This prospective randomized controlled trial evaluated the safety and efficacy of real-time feedback-controlled dosimetry (RFD)-guided selective retina therapy (SRT) in chronic central serous chorioretinopathy (CSC). " 07/01/2017 - "To evaluate the safety and efficacy of selective retina therapy (SRT) with real-time feedback-controlled dosimetry (RFD) in the treatment of chronic central serous chorioretinopathy (CSC). " 03/27/2023 - "This study evaluates the long-term effects of selective retina therapy (SRT) on the retinal pigment epithelium (RPE) and neuroretina in patients with central serous chorioretinopathy. "
4.	Light Coagulation 08/01/1997 - "The authors of previous studies on the role of photocoagulation for central serous chorioretinopathy (CSR) have based their deductions on the premise that a Snellen visual acuity of 6/6 is the end point of recovery. " 06/01/2013 - "Exacerbation of central serous chorioretinopathy following PASCAL photocoagulation." 09/01/2009 - "In a prospective study, 15 consecutive patients with central serous chorioretinopathy and single leakage points were treated with photocoagulation between 2 days and 8 weeks after onset of symptoms. " 09/01/2009 - "To investigate the effect of early photocoagulation in central serous chorioretinopathy. " 12/01/2008 - "Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage."
5.	Laser Therapy (Surgery, Laser) 02/01/2013 - "The purpose of the study was to measure the improvement in vision and contrast sensitivity in patients with central serous chorioretinopathy after macular subthreshold laser therapy. " 11/27/2023 - "To evaluate the efficacy of nondamaging subthreshold laser therapy in Korean patients with chronic central serous chorioretinopathy (cCSC). " 03/01/2023 - "To evaluate short-term efficacy of subthreshold micropulse laser therapy on chronic central serous chorioretinopathy (CSC) electrophysiologically and anatomically. " 07/01/2021 - "The aim of this article is to assess the efficacy of subthreshold micropulse laser therapy in patients with chronic central serous chorioretinopathy. " 01/01/2021 - "Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy."